IPA publishes its scientific paper “Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Protein with in vivo Efficacy” on bioRxiv
VICTORIA, British Columbia, July 22, 2021–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA ) (TSX VENTURE: IPA ) today announced new results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
The Company anticipated viral evolution leading to novel SARS-CoV-2 variants of concern throughout the design of their PolyTope SARS-CoV-2 therapeutic cocktail, aiming to minimize the risk of mutagenic escape (a reduction or elimination in the efficacy of a therapy or vaccine by virus mutation). As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPA’s multi-antibody cocktail towards SARS-CoV-2 variants of concern. IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPA’s TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2). Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant with the majority showing maintained binding. These results are consistent with previously announced binding data towards other SARS-CoV-2 mutants, including variants of concern Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants. These binding data, combined with the maintained neutralization potency of IPA’s TATX-03 to variants of concern, supports the Company’s expectation that rationally designed multi-membered antibody cocktails are more sustainable, e.g. will be functionally less prone to escape-by-one mutations.
“The data from IPA’s screenings on the variants of concern speak to the importance of targeting diversified epitopes on the spike trimer for treatment sustainability and resilience of our PolyTope cocktail,” stated Dr . Ilse Roodink, IPA’s Chief Scientific Officer and Global Program Director for COVID Research. “Our TATX-03 cocktail is rationally designed for broad epitope coverage relying on multiple antibodies, which have shown in pre-clinical studies to work synergistically together, to reduce the risk of mutagenic escape, and have the potential to reduce the risk of new variants. We believe this strategy of multi-antibody cocktails is more crucial now with the surge of new variants of concern and breakthrough cases.”
IPA’s paper “Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy” (https://doi.org/10.1101/2021.07.20.45285…) describes the Company’s approach to designing TATX-03, including the extensive characterization studies and in vivo efficacy trials which supported the rational design of the antibody cocktail, and which demonstrates sustained pre-clinical efficacy to emerging variants of concern.
ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit http://www.immunoprecise.com